<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1756">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05364307</url>
  </required_header>
  <id_info>
    <org_study_id>Apheleia-001</org_study_id>
    <nct_id>NCT05364307</nct_id>
  </id_info>
  <brief_title>Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)</brief_title>
  <official_title>Identification of Mild Cognitive Impairment (MCI) and Early Alzheimer's Disease (AD) Patients With a High Probability of Meeting Eligibility Criteria for a Therapeutic Alzheimer's Disease Clinical Trial (APHELEIA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Alzheimer's Platform Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Alzheimer's Platform Foundation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apheleia-001 is a prescreener that aims to identify and characterize participants with&#xD;
      reported cognitive impairment using demographic information, clinical history, brief&#xD;
      cognitive assessments, and blood-based biomarkers to distinguish appropriate participants for&#xD;
      referral to a therapeutic AD clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2022</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine number of patients eligible for therapeutic Alzheimer's Disease clinical trial</measure>
    <time_frame>Throughout study completion, an average of 45 days</time_frame>
    <description>Participants with reported memory complaints and/or cognitive impairment will provide demographic information, clinical history, complete brief cognitive assessments, and provide blood-based biomarkers</description>
  </primary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Memory Loss</condition>
  <condition>Memory Disorders</condition>
  <condition>Memory Impairment</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prescreener database</intervention_name>
    <description>Identify and characterize participants with reported memory complaints and/or cognitive impairment to determine the probability of randomization into a therapeutic AD clinical trial.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Aβ 42/40, Aβ 42, Aβ40, ApoE4, APS&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Approximately 3,000 participants.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Participants and/or a legally authorized representative (LAR) must provide signed&#xD;
             and dated informed consent and authorization to use personal health information in&#xD;
             accordance with local and national guidance and regulations;&#xD;
&#xD;
             2. Male or female 50 to 90 years of age (inclusive) at the time of consent;&#xD;
&#xD;
             3. Participants must have a Mini-Mental State Exam (MMSE) score of 20 to 28 inclusive;&#xD;
&#xD;
             4. Progressive cognitive complaints must be reported by participant or caregiver;&#xD;
&#xD;
             5. Participants must be willing to comply with all procedures as outlined in the&#xD;
             informed consent, including blood sampling, genetic testing, and storage of&#xD;
             biospecimens for future research;&#xD;
&#xD;
             6. Fluency in the language of the tests used at the site;&#xD;
&#xD;
             7. Participants must be interested in participating in clinical research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Participants who, in the opinion of the Investigator, have serious or unstable&#xD;
             medical conditions that would prohibit their completion of all prescreening procedures&#xD;
             and data collection;&#xD;
&#xD;
             2. Participants who are currently enrolled in another clinical study.&#xD;
&#xD;
             3. Participants who have serious or unstable medical conditions that would likely&#xD;
             preclude their participation in an interventional research trial;&#xD;
&#xD;
             4. Participants who have reported or have a known negative amyloid PET scan in the&#xD;
             past 24 months;&#xD;
&#xD;
             5. Participants with history of stroke within 6 months of prescreening;&#xD;
&#xD;
             6. Participants with an uncontrolled seizure disorder, unexplained blackouts, OR&#xD;
             history of a seizure within 6 months (subjects with a history of pediatric febrile&#xD;
             seizure, benign rolandic epilepsy may participate);&#xD;
&#xD;
             7. Participants with a history or evidence of a malignancy within the 2 years prior to&#xD;
             prescreening. Subjects with indolent malignancies (e.g., basal cell carcinoma or&#xD;
             squamous cell carcinoma) or malignancies considered to be cured and not actively&#xD;
             treated with anti-cancer therapy or radiotherapy are permitted to enroll;&#xD;
&#xD;
             8. Participants with known or suspected alcohol or drug abuse or dependence within 2&#xD;
             years of prescreening;&#xD;
&#xD;
             9. Participants with a reported suicidal attempt within 2 years of prescreening), or&#xD;
             any unstable psychiatric symptoms (e.g., uncontrolled depression);&#xD;
&#xD;
             10. Participants who have participated in a clinical trial of any potential disease&#xD;
             modifying AD treatment and received active drug within 6 months prior to prescreening;&#xD;
&#xD;
             11. Participants who have any neurological disorder affecting the central nervous&#xD;
             system, other than AD, that may be contributing to cognitive impairment (e.g.,&#xD;
             Parkinson's disease, other dementias, multiple concussions or seizures) as deemed&#xD;
             significant by the Investigator;&#xD;
&#xD;
             12. Participants with known history of hepatitis C virus, hepatitis B virus, human&#xD;
             immunodeficiency virus (HIV) or other immunodeficiencies;&#xD;
&#xD;
             13. Participants that have previously been consented to this protocol;&#xD;
&#xD;
             14. Participants with a hypersensitivity to mAb treatments, protein derived from a&#xD;
             mAb, or immunoglobulin therapy;&#xD;
&#xD;
             15. Participants with allergies to diphenhydramine, epinephrine, and&#xD;
             methylprednisolone;&#xD;
&#xD;
             16. Participants who are direct employees or family members of direct employees of the&#xD;
             participating investigators' sites;&#xD;
&#xD;
             17. Participants who are direct employees of the Sponsor;&#xD;
&#xD;
             18. Participants who, in the opinion of the Investigator, are unable to complete&#xD;
             cognitive testing due to inadequate visual or auditory acuity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Allison Jolkovski</last_name>
    <phone>6025493489</phone>
    <email>ajolkovski@globalalzplatform.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pacific Research Network</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Martinez</last_name>
      <phone>619-294-4302</phone>
    </contact>
    <contact_backup>
      <last_name>Shanisha Miller</last_name>
      <phone>619-294-4302</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Syrentis Clinical Research</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlene Preyer</last_name>
      <phone>714-542-3008</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Visionary Investigator's Network</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Macias</last_name>
      <phone>305-933-5993</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charter Research</name>
      <address>
        <city>Lady Lake</city>
        <state>Florida</state>
        <zip>32159</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Nix</last_name>
      <phone>352-775-1000</phone>
    </contact>
    <contact_backup>
      <last_name>Kisha Kaffenberger</last_name>
      <phone>352-775-1000</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>JEM Research Institute</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janette Bossaers</last_name>
      <phone>561-968-2933</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ClinCloud, LLC</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valery Crespo-Matos</last_name>
      <phone>407-636-4031</phone>
    </contact>
    <contact_backup>
      <last_name>Angel Perez</last_name>
      <phone>407-636-4031</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>K2 Medical Research</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jawad Alqerem</last_name>
      <phone>407-500-5252</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merritt Island Medical Research</name>
      <address>
        <city>Merritt Island</city>
        <state>Florida</state>
        <zip>32952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Mabry</last_name>
      <phone>321-305-5015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandy Roomy</last_name>
      <phone>352-629-5800</phone>
    </contact>
    <contact_backup>
      <last_name>Allison Morgan</last_name>
      <phone>352-629-5800</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>ClinCloud, LLC</name>
      <address>
        <city>Viera</city>
        <state>Florida</state>
        <zip>32940</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariah Robison</last_name>
      <phone>407-680-0534</phone>
    </contact>
    <contact_backup>
      <last_name>Anna Manturova</last_name>
      <phone>407-680-0534</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Premiere Research Institute at Palm Beach Neurology</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Reiser</last_name>
      <phone>561-845-0500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Conquest Research</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa O'Neill</last_name>
      <phone>407-848-3845</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charter Research</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Martinez</last_name>
      <phone>407-337-1000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>iResearch</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Certain</last_name>
      <phone>404-537-1281</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quest Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Bardram</last_name>
      <phone>248-957-8940</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Padilla</last_name>
      <phone>210-949-0122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Re:Cognition Health</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Wu</last_name>
      <phone>703-520-9703</phone>
    </contact>
    <contact_backup>
      <last_name>Monica Bland</last_name>
      <phone>703-520-9703</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Baek MJ, Kim K, Park YH, Kim S. The Validity and Reliability of the Mini-Mental State Examination-2 for Detecting Mild Cognitive Impairment and Alzheimer's Disease in a Korean Population. PLoS One. 2016 Sep 26;11(9):e0163792. doi: 10.1371/journal.pone.0163792. eCollection 2016.</citation>
    <PMID>27668883</PMID>
  </reference>
  <reference>
    <citation>Berry CC. A tutorial on confidence intervals for proportions in diagnostic radiology. AJR Am J Roentgenol. 1990 Mar;154(3):477-80. Review.</citation>
    <PMID>2106207</PMID>
  </reference>
  <reference>
    <citation>Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018. Review.</citation>
    <PMID>29653606</PMID>
  </reference>
  <reference>
    <citation>Kantarci K. Molecular imaging of Alzheimer disease pathology. AJNR Am J Neuroradiol. 2014 Jun;35(6 Suppl):S12-7. doi: 10.3174/ajnr.A3847. Epub 2014 Feb 6. Review.</citation>
    <PMID>24503555</PMID>
  </reference>
  <reference>
    <citation>Niemantsverdriet E, Valckx S, Bjerke M, Engelborghs S. Alzheimer's disease CSF biomarkers: clinical indications and rational use. Acta Neurol Belg. 2017 Sep;117(3):591-602. doi: 10.1007/s13760-017-0816-5. Epub 2017 Jul 27. Review.</citation>
    <PMID>28752420</PMID>
  </reference>
  <reference>
    <citation>O'Bryant SE, Humphreys JD, Smith GE, Ivnik RJ, Graff-Radford NR, Petersen RC, Lucas JA. Detecting dementia with the mini-mental state examination in highly educated individuals. Arch Neurol. 2008 Jul;65(7):963-7. doi: 10.1001/archneur.65.7.963.</citation>
    <PMID>18625866</PMID>
  </reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>May 4, 2022</study_first_submitted>
  <study_first_submitted_qc>May 4, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2022</study_first_posted>
  <last_update_submitted>November 7, 2022</last_update_submitted>
  <last_update_submitted_qc>November 7, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Memory Loss</keyword>
  <keyword>Memory Disorder</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Early Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Memory Disorders</mesh_term>
    <mesh_term>Amnesia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

